U.S. markets closed
  • S&P 500

    4,128.80
    +31.63 (+0.77%)
     
  • Dow 30

    33,800.60
    +297.00 (+0.89%)
     
  • Nasdaq

    13,900.19
    +70.89 (+0.51%)
     
  • Russell 2000

    2,243.47
    +0.87 (+0.04%)
     
  • Crude Oil

    59.34
    +0.02 (+0.03%)
     
  • Gold

    1,744.10
    -0.70 (-0.04%)
     
  • Silver

    25.33
    0.00 (0.00%)
     
  • EUR/USD

    1.1905
    -0.0016 (-0.13%)
     
  • 10-Yr Bond

    1.6660
    +0.0340 (+2.08%)
     
  • GBP/USD

    1.3706
    -0.0028 (-0.20%)
     
  • USD/JPY

    109.6300
    +0.3660 (+0.33%)
     
  • BTC-USD

    59,671.89
    -134.60 (-0.23%)
     
  • CMC Crypto 200

    1,235.89
    +8.35 (+0.68%)
     
  • FTSE 100

    6,915.75
    -26.47 (-0.38%)
     
  • Nikkei 225

    29,768.06
    +59.06 (+0.20%)
     

Merus to Participate in a Fireside Chat at the 33rd Annual Roth Conference

  • Oops!
    Something went wrong.
    Please try again later.
Merus N.V.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 08, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer, will participate in a fireside chat at the 33rd Annual Roth Conference on Monday, March 15 at 2:00 p.m. ET.

The live webcast of the presentation will be available on the Investors page of the Company's website, https://ir.merus.nl. An archived presentation will be available on the Merus website for a limited time.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, http://www.merus.nl and https://twitter.com/MerusNV.

CONTACT: Investor and Media Inquiries: Jillian Connell Merus N.V. Investor Relations and Corporate Communications 617-955-4716 j.connell@merus.nl Kathleen Farren Merus N.V. Communications Specialist 617-230-4165 k.farren@merus.nl